Business Wire

 QCT, Radisys and Intel Deliver vRAN Solution for 5G

Share

Quanta Cloud Technology (QCT), a global data center solution provider, announced OmniRAN, its virtualized radio access network (vRAN) solution developed with its long-term partners, Intel and Radisys. The solution uses Intel FlexRAN , a cloud-enabled wireless access virtual network functions reference implementation, and Radisys Connect 5G RAN software, a disaggregated RAN architecture for promoting 4G, 5G and IoT to build a cloud-native vRAN based on 3rd Gen Intel Xeon Scalable Processors running on QCT EGX63IS-1U servers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629005459/en/

To deliver low-latency and power-efficient services with the flexibility to increase or decrease capacity based on the volume of real-time traffic demands, Intel’s vRAN dedicated accelerator, ACC100, for forward error correction (FEC) acceleration is also an essential part of the integrated solution. Intel’s 5G optimized network adapter, codenamed Westport Channel, is also implemented for accurate time synchronization without the added complexity or expenses that come with specialty timing hardware. This validated combination on QCT EGX63IS-1U extends distributed unit (DU) capabilities to support multi-cell and multi-RRU 5G scenarios, delivering reliable performance for various network workloads.

As operators are increasingly looking for ways to accelerate their 5G network deployments by leveraging disaggregated and open reference architecture solutions, OpenRAN-based OmniRAN is designed to minimize the challenges of infrastructure deployment and maximize value of ownership. OmniRAN has already been successfully deployed in smart manufacturing use cases such as safety AI for environment control, high-resolution streaming for quality control, AR goggles for maintenance and repair, and autonomous guided vehicles (AGV) for equipment transport. Not only does OmniRAN provide improved performance such as wider coverage and enhanced mobility, but also offer centralized management as well as greater scalability and deployment flexibility while achieving significant cost savings.

“QCT works closely with its partners to ensure that customers can always stay ahead of the game,” said Mike Yang, President of QCT. “Incorporating the newest technologies and features from Intel and Radisys, QCT’s latest vRAN solution improves capital and operational efficiencies by optimizing resource utilization and making software-defined management and orchestration possible.”

“Open 5G networks are the next step for customers across many sectors, and Radisys, along with our partners, is providing open, disaggregated and virtualized RAN solutions to meet varying business demands,” said Munish Chhabra, head of Mobility Software and Services Business, Radisys. “We are excited to power the QCT vRAN solution through our market first Release 16 Radisys 5G software stack. The integrated solution enables mobile operators and enterprises to benefit from reduced costs, improved network efficiencies, and faster time-to-market of new services that open APIs and open architectures provide.”

“This demonstration from Intel, QCT, and Radisys is important for accelerating broader adoption of 5G,” said Cristina Rodriguez, Intel VP and GM of Data Center Group, Wireless Access Network Division. “By defining the FlexRAN reference architecture and collaborating with our Intel Network Builders, Intel is expanding its growing portfolio of technology and ecosystem to ensure interoperability, enhanced performance, and reduced overhead for service providers all over the globe.”

For more information visit https://go.qct.io/telco/.

About Quanta Cloud Technology (QCT)

Quanta Cloud Technology (QCT) is a global data center solution provider. We combine the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds.

Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries. Other names and brands may be claimed as the property of others.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Danny Chang
Danny_Chang@quantatw.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye